马骥 余惠云 刘颖 赵庆丽.二甲双胍抗肿瘤效应的基础与临床研究进展[J].,2015,15(33):6587-6589 |
二甲双胍抗肿瘤效应的基础与临床研究进展 |
Basic and Clinical Research Progress of Metformin in Anti-tumor Effects |
|
DOI: |
中文关键词: 二甲双胍 抗肿瘤效应 基础与临床研究 |
英文关键词: Metformin Anti-tumor effects Basic and clinical study |
基金项目:国家自然科学基金项目(81202085);兰州市科技计划项目(2014-1-39) |
|
摘要点击次数: 667 |
全文下载次数: 0 |
中文摘要: |
二甲双胍(Metformin)是一种胰岛素增敏剂,临床上主要用于2 型糖尿病的治疗。越来越多的证据表明,二甲双胍能够发挥
抗肿瘤效应,它通过活化磷酸腺苷蛋白激酶(AMPK),阻断哺乳动物雷帕霉素靶蛋白(mTOR)信号通路抑制肿瘤细胞的生长,并
且参与细胞周期、凋亡、血管新生等多种生物学行为。不仅如此,二甲双胍的抗肿瘤临床研究也不断出现,包括大样本回顾性研究
和前瞻性研究。这些研究数据不仅为二甲双胍抗肿瘤效应提供了有益的证据支持,也为二甲双胍及其介导的抗肿瘤分子信号途
径的阐明奠定了理论依据。 |
英文摘要: |
Metformin, an insulin sensitizer, is a biguanide commonly used to treat type 2 diabetes mellitus. Emerging evidence
suggests that metformin may activate AMPK and inhibit mTOR signaling to exert anti-tumor effects and inhibit tumor cells growth.
Metformin also plays some roles on cell cycle, apoptosis, and angiogenesis of tumor cells. Moreover, anti-tumor clinical studies of
metformin are more and more, including retrospective study of large sample and prospective study. These studies not only provide helpful
evidence for anti-tumor effects of metformin, but also give the theoretical basis for clarifying the molecular signal pathway of anti-tumor
induced by metformin. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |